DailyIQ
|
Sector:HealthcareAll sectors
Last updated 6 minutes ago

ABBV·AbbVie Inc.

$.
-. (-.%)
After Hours
High
$251.90
Open
$251.01
Market Cap
441.54B
52W High
$261.63
Low
$245.05
P. Close
$248.00
P/E
121.47
52W Low
$184.63
Fwd P/E
15.24
DailyIQ Est.
$271.84
Technical Score (1D)
82
BUY
News Sentiment
83
BULLISH
AbbVie’s purchase of West Pharmaceutical Services’ SmartDose 3.5 mL On‑Body Delivery System rights expands its drug‑delivery portfolio and gives the company control over a high‑volume wearable injector platform, potentially accelerating the commercialization of its injectable biologics. The integration of the SmartDose platform and any realized cost synergies will be a key focus in the next earnings report, so traders should watch the timeline and financial impact disclosed there. A simultaneous increase in Kestra Advisory Services’ holdings signals institutional confidence in AbbVie’s prospects, which may provide short‑term support for the stock. AbbVie’s Q1 2026 revenue beat, driven by its specialty‑pharma focus, reinforces the narrative that investors favor high‑growth specialty plays over broader portfolios, and this context helps explain the recent analyst upgrades. B of A Securities upgraded AbbVie to a Buy and lifted the price target to $276, citing confidence in the pipeline and earnings outlook, a sentiment echoed by RBC’s raise of the target to $280 and Wells Fargo’s lift to $295, all while maintaining outperform or overweight ratings. RBC’s expectation that Q2 results will align with consensus suggests stable growth, but the robust pipeline still underpins the bullish price targets. The convergence of multiple upgrades and target hikes indicates a consensus that AbbVie’s earnings outlook remains favorable, yet the lack of new catalysts in Q2 means the next earnings release will be critical for confirming or revising that view. Watch for any regulatory updates on key drug candidates and for the integration progress of the SmartDose platform, as both could materially influence AbbVie’s near‑term performance.
Earnings Summary
AbbVie, headquartered in North Chicago, is a global biopharmaceutical company that develops and commercializes a broad portfolio of therapies across autoimmune, oncology, neuroscience, eye care, hepatitis C, and gastrointestinal disorders, positioning it within the drug manufacturers sector. In the most recent two quarters with complete data, Q1 2026 reported EPS of $2.65 and revenue of $15.00 billion, a decline from Q2 2025’s EPS of $2.97 and revenue of $15.42 billion, and both figures fell relative to the prior year’s Q4 2025 EPS of $2.71 and revenue of $16.62 billion; the company’s EPS beat estimates in five of the last six quarters, but Q1 2026 missed the $3.74 estimate, marking a shift after a streak of consistent beats. Historically, AbbVie has delivered double‑digit revenue growth and EPS expansion from Q4 2024 through Q4 2025, with revenue rising from $15.10 billion to $16.62 billion and EPS from $2.16 to $2.71, yet the most recent quarter shows a reversal in both metrics, suggesting a slowdown in growth momentum. Recent news highlights a bullish earnings outlook of $3.76 EPS and $16.79 billion revenue for the upcoming quarter, a strategic acquisition of West Pharmaceutical’s SmartDose platform aimed at accelerating drug‑delivery innovation, and a European Commission approval of the expanded Tepkinly indication, all of which could influence future revenue streams and cost structures. Investors should watch for the Q2 2026 earnings release to assess whether the SmartDose integration delivers operational synergies, monitor regulatory developments that could affect the newly approved oncology indication, and evaluate how the company’s guidance aligns with the recent valuation upgrades, as these factors will shape the next phase of AbbVie’s earnings trajectory.

EPS

EstBeatMiss
$1.49$2.13$2.76$3.40$4.03Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$3.63 - -
Q1'26$3.74$2.65-29.2%
Q4'25$2.71$2.71+0.2%
Q3'25$1.78$1.86+4.2%
Q2'25$2.91$2.97+2.1%
Q1'25$2.40$2.46+2.6%

Revenue

EstBeatMiss
$12.8B$14.0B$15.2B$16.4B$17.6BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$17.1B - -
Q1'26$16.8B$15.0B-10.7%
Q4'25$16.7B$16.6B-0.8%
Q3'25 - $15.8B -
Q2'25 - $15.4B -
Q1'25 - $13.3B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ABBV Stock Snapshot

ABBV is currently trading at $248.40, giving AbbVie Inc. a market cap of 441.54B and a P/E ratio of 121.5. Today's range spans $245.05–$251.90, with shares opening at $251.01 and moving up $0.40 (0.2%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 83/100.

Over the past year ABBV has traded between $184.63 and $261.63 - the current price is +34.5% off the 52-week low and -5.1% from the high. 41 analysts cover the stock with a Buy consensus and a mean 12-month target of $259.46 (range $200.00–$328.00), implying upside of +4.5%.

Short interest data on large-cap Healthcare names like ABBV (441.54B market cap) becomes relevant when the technical picture turns bullish - a BUY on 82/100 with bullish sentiment (83/100) is exactly the kind of setup that makes shorts nervous. Price at $248.40 (in the upper portion of its 52-week range in $184.63–$261.63). The current P/E ratio stands at 121.5. Short covering in a bullish technical phase can add a secondary momentum layer on top of genuine long-side conviction - a dynamic worth monitoring in the current setup.

Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (82/100) and news sentiment (83/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $248.40 (in the upper portion of its 52-week range), ABBV's position within the $184.63–$261.63 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.